Verma, PriyankaJoshi, HemantSingh, TejveerSharma, BuntySharma, UjjawalRamniwas, SeemaRana, RashmiGupta, MadhuKaur, GinpreetTuli, Hardeep Singh2024-01-212024-08-142024-01-212024-08-142023-08-1128129810.1007/s00210-023-02660-whttps://kr.cup.edu.in/handle/32116/4264Patients with glioblastoma multiforme and anaplastic astrocytoma are treated with temozolomide. Although it has been demonstrated that temozolomide increases GBM patient survival, it has also been connected to negative immune-related adverse effects. Numerous research investigations have shown that flavonoids have strong antioxidant and chemo-preventive effects. Consequently, it might lessen chemotherapeutic medicines� side effects while also increasing therapeutic effectiveness. The need for creating innovative, secure, and efficient drug carriers for cancer therapy has increased over time. Recent research indicates that exosomes have enormous potential to serve as carriers and cutting-edge drug delivery systems to the target cell. In recent years, researchers have been paying considerable attention to exosomes because of their favorable biodistribution, biocompatibility, and low immunogenicity. In the present review, the mechanistic information of the anti-glioblastoma effects of temozolomide and flavonoids coupled with their exosomal delivery to the targeted cell has been discussed. In addition, we discuss the safety aspects of temozolomide and flavonoids against glioma. The in-depth information of temozolomide and flavonoids action via exosomal delivery can unravel novel strategies to target Glioma. � 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.en-USAnti-glioblastoma effectsBlood�brain barrierExosomeDrug carriersFlavonoidsGliomaTemozolomideReviewhttps://link.springer.com/10.1007/s00210-023-02660-w